NCAM-1

NCAM-1 Overview

English NameNeural cell adhesion molecule 1Approved Drugs0
Drugs in Clinical Trials6Target SynonymNeural cell adhesion molecule 1,CD56,NCAM1,NCAM,Neural Cell Adhesion Molecule, NCAM,CD56 Antigen,N-CAM-1,MSK39,NCAM-1,Antigen Recognized By Monoclonal Antibody 5.1H11
Highest Development StagePhase 2 Clinical
English NameNeural cell adhesion molecule 1
Target SynonymNeural cell adhesion molecule 1,CD56,NCAM1,NCAM,Neural Cell Adhesion Molecule, NCAM,CD56 Antigen,N-CAM-1,MSK39,NCAM-1,Antigen Recognized By Monoclonal Antibody 5.1H11
Approved Drugs0
Drugs in Clinical Trials6
Highest Development StagePhase 2 Clinical

NCAM-1 Background

NCAM1 belongs to the immunoglobulin superfamily of adhesion molecules. A wide range of alternatively spliced NCAM1 messenger RNAs (mRNAs) has been described to date, but only the 120-, 140-, and 180- kDa isoforms are commonly expressed. NCAM1 plays an important role in the regulation of neurogenesis, neurite outgrowth, proliferation, and cell migration, however, its function in hematopoiesis, including NK cells, is poorly understood. NCAM1 signaling is mediated either by homophilic or heterophilic interactions with fibroblast growth factor receptor (FGFR), L1-CAM, N-cadherin and other components of the extracellular matrix. Upon activation, NCAM1 triggers a variety of signaling cascades including FYN–focal adhesion kinase (FAK), MAPK, and phosphatidylinositol 3-kinase (PI3K) pathways.

NCAM-1 Synonyms

CD56,MSK39,NCAM1,N-CAM-1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Lorvotuzumab mertansineBB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1Phase 2 ClinicalImmunogen IncCarcinoma, Merkel Cell; Leukemia; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Ovarian Neoplasms; Pulmonary Blastoma; Rhabdomyosarcoma; Sarcoma, Synovial; Small Cell Lung Carcinoma; Wilms Tumor
Details
EB-DART-NK01EB-DART-NK01Phase 2 ClinicalBeijing BiotechSmall Cell Lung Carcinoma
Details
CUBT-906CUBT-906Phase 2 ClinicalCurative Biotechnology IncGlioblastoma
Details
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR GD2/CD56Phase 2 ClinicalShenzhen Geno-Immune Medical InstituteNeoplasms
Details
IN-B015IN-B-015; IN-B00004Phase 1 ClinicalHK inno.N CorporationNeoplasms
Details
DXC-006DXC-006; DAC-006Phase 1 ClinicalHangzhou Dac Biotech Company LtdHematologic Neoplasms; Lung Neoplasms; Solid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information